New hope for HIV patients with rare brain disease?
NCT ID NCT00120367
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a powerful HIV drug called FUZEON® to standard antiretroviral therapy could help people with HIV who also have a rare brain infection called PML. PML is caused by a virus that attacks the brain when the immune system is weak. The goal was to see if the stronger drug combination could stop the infection from getting worse. The study included 30 adults in France and followed them for one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Medecine interne et Maladies Infectieuses, Hopital Bicetre
Le Kremlin-Bicêtre, 94270, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer-led prevention: can gancheros help stop HIV, hepatitis c, and overdose in NYC?
- Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
- Long-acting HIV shot studied in patients with severe kidney problems
- Can two hours of mindfulness ease chronic pain in HIV patients?
- Can a clinic-and-social-media campaign boost HIV prevention among black women?
- Choice of Long-Acting HIV prevention could transform care for young people in rural south africa